Team Work: Pfizer, Abbott Gain Swift Approvals For Lung Cancer Drug/Test Combo
This article was originally published in The Gray Sheet
Executive Summary
Following simultaneous and swift FDA approvals, Abbott Molecular Diagnostics is launching its Vysis ALK molecular test to identify the small percentage of non-small-cell lung cancer patients who would respond to Pfizer’s Xalkori (crizotinib) cancer drug.
You may also be interested in...
News Briefs: Siemens-Pfizer Dx Pact; Pancreatic Stent; AtriCure Acquisition
Siemens teams with Pfizer on companion Dx. XLumena gains pancreatic stent approval. AtriCure acquires Estech. More news.
News In Brief
Roche’s melanoma companion diagnostic approved
FDA Companion Dx Draft Guidance: Broad In Scope, Limited In Detail
FDA's draft guidance on the development of companion diagnostics for drug therapies, released July 12, delivers on a promise to publicly outline how it will address review of those products, but at only 12 pages, it has left some in industry longing for more insight.